In gastric and prostate cancers, overexpression of DNA damage inducible transcript 4 (DDIT4) [65] and the metallothionein MT1X [66] have both been identified to associate with poorer prognosis and/or increased metastatic phenotypes. Here, MT1X is linked to prostate cancer.